Translational Development Acquisition Corp. Ordinary Shares Net Assets
Translational Development Acquisition Corp. Ordinary Shares net assets. Based on the latest financial reports, Translational Development Acquisition Corp. Ordinary Shares (TDAC) has net assets worth $149.58 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($157.37 Million) and total liabilities ($7.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Translational Development Acquisition Co growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $149.58 Million |
| % of Total Assets | 95.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
Net assets of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025. This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See Translational Development Acquisition Co balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Translational Development Acquisition Corp. Ordinary Shares (2022–2025)
The table below shows the annual net assets of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2025. For live market cap and overall valuation, see Translational Development Acquisition Co market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $175.12 Million | +3.77% |
| 2024-12-31 | $168.75 Million | +33341.43% |
| 2023-12-31 | $-507.66K | -2196.26% |
| 2022-12-31 | $-22.11K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Translational Development Acquisition Corp. Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 649546600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Translational Development Acquisition Corp. Ordinary Shares Net Assets Breakdown (December 2025)
Translational Development Acquisition Corp. Ordinary Shares net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $181.66 Million | 103.74% |
| Total Equity | $175.12 Million | 100.00% |
Translational Development Acquisition Corp. Ordinary Shares Competitors by Market Cap
The table below lists competitors of Translational Development Acquisition Corp. Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xsolla SPAC 1 Class A Ordinary Shares
NASDAQ:XSLL
|
$208.94 Million |
|
Jiangxi Changyun Co Ltd
SHG:600561
|
$208.97 Million |
|
GemVax&KAEL Co.Ltd
KQ:082270
|
$209.11 Million |
|
OP Bancorp
NASDAQ:OPBK
|
$209.20 Million |
|
Alta Equipment Group Inc
NYSE:ALTG
|
$208.88 Million |
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
$208.74 Million |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
$208.62 Million |
|
Coca Cola HBC AG
LSE:CCH
|
$208.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Translational Development Acquisition Corp. Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 168,752,776 to 175,115,203, a change of 6,362,427 (3.8%).
- Net income of 6,362,427 contributed positively to equity growth.
- Dividend payments of 7,306,965 reduced retained earnings.
- Other comprehensive income decreased equity by 16,880,000,000.
- Other factors increased equity by 16,887,306,965.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $6.36 Million | +3.63% |
| Dividends Paid | $7.31 Million | -4.17% |
| Other Comprehensive Income | $-16.88 Billion | -9639.37% |
| Other Changes | $16.89 Billion | +9643.54% |
| Total Change | $- | 3.77% |
Book Value vs Market Value Analysis
This analysis compares Translational Development Acquisition Corp. Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-0.01 | $10.82 | x |
| 2023-12-31 | $-0.13 | $10.82 | x |
| 2024-12-31 | $41.67 | $10.82 | x |
| 2025-12-31 | $10.15 | $10.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Translational Development Acquisition Corp. Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (3.63%) is above the historical average (0.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-68.45K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-434.78K |
| 2024 | -0.04% | 0.00% | 0.00x | 1.04x | $-16.95 Million |
| 2025 | 3.63% | 0.00% | 0.00x | 1.04x | $-11.15 Million |
Industry Comparison
This section compares Translational Development Acquisition Corp. Ordinary Shares's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $187,262,630
- Average return on equity (ROE) among peers: -2.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Translational Development Acquisition Corp. Ordinary Shares (TDAC) | $149.58 Million | 0.00% | 0.05x | $208.88 Million |
| Artius II Acquisition Inc. (AACB) | $-60.27K | 0.00% | 0.00x | $234.83 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $269.37 Million |
| Armada Acquisition Corp. II Class A Ordinary Shares (AACI) | $16.83 Million | -1.90% | 0.51x | $257.52 Million |
| Abony Acquisition Corp. I Class A Ordinary Share (AACO) | $-74.71 | 0.00% | 0.00x | $236.95 Million |
| Apogee Acquisition Corp Class A Ordinary Shares (AACP) | $-13.88 | 0.00% | 0.00x | $178.97 Million |
| Ares Acquisition Corporation II (AACT) | $502.67 Million | 0.00% | 0.05x | $587.05 Million |
| AA Mission Acquisition Corp. (AAM) | $813.70 Million | -27.34% | 2.19x | $312.83K |
| Altenergy Acquisition Corp (AEAE) | $-12.44 Million | 0.00% | 0.00x | $72.22 Million |
| Activate Energy Acquisition Corp. Class A Ordinary Share (AEAQ) | $223.53 Million | 0.00% | 0.04x | $238.81 Million |
| American Exceptionalism Acquisition Corp. A (AEXA) | $328.45 Million | 0.00% | 0.06x | $373.45 Million |
About Translational Development Acquisition Corp. Ordinary Shares
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.